Rapid development of hypertension by sorafenib: Toxicity or target?

Benjamin D. Humphreys; Michael B. Atkins

doi:10.1158/1078-0432.CCR-09-1717

Rapid development of hypertension by sorafenib: Toxicity or target?

Benjamin D. Humphreys, Michael B. Atkins

Research output: Contribution to journal › Comment/debate

51 Scopus citations

Abstract

Blood pressure elevation is likely a pharmacodynamic marker of VEGF signaling pathway (VSP) inhibition and could be useful for optimizing safe and effective VSP inhibitor dosing. Blood pressure rises on the first day of treatment, facilitating design and interpretation of future trials aiming to correlate blood pressure changes with clinical outcomes.

Original language	English
Pages (from-to)	5947-5949
Number of pages	3
Journal	Clinical Cancer Research
Volume	15
Issue number	19
DOIs	https://doi.org/10.1158/1078-0432.CCR-09-1717
State	Published - Oct 1 2009

Access to Document

10.1158/1078-0432.CCR-09-1717

Cite this

@article{8d7245e0e59a488b9f1f478da2d31e56,

title = "Rapid development of hypertension by sorafenib: Toxicity or target?",

abstract = "Blood pressure elevation is likely a pharmacodynamic marker of VEGF signaling pathway (VSP) inhibition and could be useful for optimizing safe and effective VSP inhibitor dosing. Blood pressure rises on the first day of treatment, facilitating design and interpretation of future trials aiming to correlate blood pressure changes with clinical outcomes.",

author = "Humphreys, {Benjamin D.} and Atkins, {Michael B.}",

year = "2009",

month = oct,

day = "1",

doi = "10.1158/1078-0432.CCR-09-1717",

language = "English",

volume = "15",

pages = "5947--5949",

journal = "Clinical Cancer Research",

issn = "1078-0432",

number = "19",

}

TY - JOUR

T1 - Rapid development of hypertension by sorafenib

T2 - Toxicity or target?

AU - Humphreys, Benjamin D.

AU - Atkins, Michael B.

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Blood pressure elevation is likely a pharmacodynamic marker of VEGF signaling pathway (VSP) inhibition and could be useful for optimizing safe and effective VSP inhibitor dosing. Blood pressure rises on the first day of treatment, facilitating design and interpretation of future trials aiming to correlate blood pressure changes with clinical outcomes.

AB - Blood pressure elevation is likely a pharmacodynamic marker of VEGF signaling pathway (VSP) inhibition and could be useful for optimizing safe and effective VSP inhibitor dosing. Blood pressure rises on the first day of treatment, facilitating design and interpretation of future trials aiming to correlate blood pressure changes with clinical outcomes.

UR - http://www.scopus.com/inward/record.url?scp=70349685095&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-09-1717

DO - 10.1158/1078-0432.CCR-09-1717

M3 - Comment/debate

C2 - 19789317

AN - SCOPUS:70349685095

SN - 1078-0432

VL - 15

SP - 5947

EP - 5949

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 19

ER -

Rapid development of hypertension by sorafenib: Toxicity or target?

Abstract

Access to Document

Other files and links

Fingerprint

Cite this